Q2 2022 Earnings Forecast for Apellis Pharmaceuticals, Inc. Issued By Oppenheimer (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) – Stock analysts at Oppenheimer dropped their Q2 2022 earnings estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Tuesday, May 10th. Oppenheimer analyst J. Kim now anticipates that the company will post earnings of ($1.52) per share for the quarter, down from their prior forecast of ($1.48). Oppenheimer also issued estimates for Apellis Pharmaceuticals’ Q3 2022 earnings at ($1.60) EPS, Q4 2022 earnings at ($1.64) EPS, FY2022 earnings at ($6.10) EPS, FY2023 earnings at ($5.53) EPS and FY2024 earnings at ($1.94) EPS.

A number of other research analysts have also weighed in on the company. Citigroup restated a “focus list” rating and set a $81.00 price objective on shares of Apellis Pharmaceuticals in a research report on Thursday, March 17th. JPMorgan Chase & Co. raised their price objective on Apellis Pharmaceuticals from $66.00 to $69.00 and gave the company an “overweight” rating in a research report on Monday, April 4th. The Goldman Sachs Group cut their price objective on Apellis Pharmaceuticals from $102.00 to $86.00 and set a “buy” rating for the company in a research report on Monday, March 7th. Robert W. Baird raised their price objective on Apellis Pharmaceuticals from $83.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, March 16th. Finally, Raymond James dropped their price target on Apellis Pharmaceuticals from $114.00 to $102.00 in a research report on Thursday, May 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $69.87.

Shares of Apellis Pharmaceuticals stock opened at $36.64 on Friday. The firm has a market cap of $3.90 billion, a price-to-earnings ratio of -4.56 and a beta of 1.63. The business has a 50-day moving average price of $48.27 and a 200-day moving average price of $44.32. The company has a quick ratio of 8.58, a current ratio of 8.85 and a debt-to-equity ratio of 0.41. Apellis Pharmaceuticals has a twelve month low of $27.50 and a twelve month high of $73.00.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.07). Apellis Pharmaceuticals had a negative net margin of 866.81% and a negative return on equity of 607.37%. During the same period in the previous year, the business posted ($2.32) EPS.

A number of large investors have recently modified their holdings of APLS. Harbor Investment Advisory LLC grew its holdings in Apellis Pharmaceuticals by 25.1% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,267 shares of the company’s stock worth $60,000 after purchasing an additional 254 shares during the last quarter. Metropolitan Life Insurance Co NY grew its holdings in shares of Apellis Pharmaceuticals by 1.7% during the third quarter. Metropolitan Life Insurance Co NY now owns 17,657 shares of the company’s stock valued at $582,000 after buying an additional 291 shares during the last quarter. MML Investors Services LLC grew its holdings in shares of Apellis Pharmaceuticals by 4.6% during the third quarter. MML Investors Services LLC now owns 7,970 shares of the company’s stock valued at $263,000 after buying an additional 354 shares during the last quarter. Virginia Retirement Systems ET AL grew its holdings in shares of Apellis Pharmaceuticals by 7.1% during the first quarter. Virginia Retirement Systems ET AL now owns 6,000 shares of the company’s stock valued at $305,000 after buying an additional 400 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Apellis Pharmaceuticals by 0.4% during the third quarter. Swiss National Bank now owns 133,400 shares of the company’s stock valued at $4,397,000 after buying an additional 500 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

In related news, insider Lukas Scheibler sold 11,496 shares of the business’s stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $55.05, for a total value of $632,854.80. Following the completion of the transaction, the insider now owns 52,233 shares of the company’s stock, valued at $2,875,426.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alec Machiels sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, March 15th. The stock was sold at an average price of $39.57, for a total transaction of $49,462.50. The disclosure for this sale can be found here. In the last three months, insiders sold 38,000 shares of company stock valued at $1,938,523. 9.50% of the stock is owned by insiders.

Apellis Pharmaceuticals Company Profile (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

See Also

Earnings History and Estimates for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.